← Back to Screener
Q32 Bio Inc. Common Stock (QTTB)
Price$6.65
Favorite Metrics
Price vs S&P 500 (26W)55.12%
Price vs S&P 500 (4W)-21.92%
Market Capitalization$85.58M
P/E Ratio (Annual)2.87x
All Metrics
Book Value / Share (Quarterly)$3.27
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)155.81%
Cash Flow / Share (Quarterly)$-2.61
Price vs S&P 500 (YTD)72.07%
Net Profit Margin (TTM)107.43%
EPS (TTM)$2.29
10-Day Avg Trading Volume0.27M
EPS Excl Extra (TTM)$2.29
Revenue Growth (5Y)81.88%
EPS (Annual)$2.42
ROI (Annual)-255.53%
Net Profit Margin (5Y Avg)-2984.10%
Cash / Share (Quarterly)$3.76
P/E Basic Excl Extra (TTM)2.87x
P/E Normalized (Annual)2.87x
ROA (Last FY)-51.88%
EBITD / Share (TTM)$2.33
ROE (5Y Avg)-224.01%
Operating Margin (TTM)85.38%
Cash Flow / Share (Annual)$-5.65
P/B Ratio2.04x
P/B Ratio (Quarterly)0.97x
Net Income / Employee (Annual)$1
ROA (TTM)45.06%
EV / EBITDA (TTM)1.64x
EPS Incl Extra (Annual)$2.42
Current Ratio (Annual)5.13x
Quick Ratio (Quarterly)4.31x
3-Month Avg Trading Volume0.25M
52-Week Price Return216.22%
P/E Incl Extra (TTM)2.87x
Revenue / Employee (TTM)$2
P/S Ratio (Annual)1.59x
Asset Turnover (Annual)0.01x
52-Week High$8.04
Operating Margin (5Y Avg)-2631.48%
EPS Excl Extra (Annual)$2.42
CapEx CAGR (5Y)-67.85%
26-Week Price Return63.87%
Quick Ratio (Annual)4.92x
13-Week Price Return62.50%
Total Debt / Equity (Annual)2.29x
Current Ratio (Quarterly)4.85x
Enterprise Value$46.993
Revenue / Share Growth (5Y)136.64%
Asset Turnover (TTM)0.87x
Revenue / Employee (Annual)$2
Pretax Margin (Annual)55.49%
Cash / Share (Annual)$6.50
3-Month Return Std Dev107.28%
Net Income / Employee (TTM)$1
ROE (Last FY)-840.37%
EPS Basic Excl Extra (Annual)$2.42
Total Debt / Equity (Quarterly)0.23x
EPS Incl Extra (TTM)$2.29
ROI (TTM)111.62%
P/S Ratio (TTM)1.59x
Pretax Margin (5Y Avg)-2497.64%
Revenue / Share (Annual)$4.36
Price vs S&P 500 (52W)181.12%
P/E Ratio (TTM)2.87x
Year-to-Date Return76.20%
5-Day Price Return8.13%
EPS Normalized (Annual)$2.42
ROA (5Y Avg)-56.34%
Net Profit Margin (Annual)55.49%
Month-to-Date Return-8.88%
EBITD / Share (Annual)$2.40
Operating Margin (Annual)28.48%
ROI (5Y Avg)-107.04%
P/E Excl Extra (TTM)2.87x
LT Debt / Equity (Quarterly)0.08x
EPS Basic Excl Extra (TTM)$2.29
P/B Ratio (Annual)8.38x
Pretax Margin (TTM)107.43%
Book Value / Share (Annual)$0.42
Price vs S&P 500 (13W)59.63%
Beta0.03x
P/FCF (Annual)18.93x
Revenue / Share (TTM)$4.26
ROE (TTM)137.41%
52-Week Low$1.34
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
QTTBQ32 Bio Inc. Common Stock | 1.59x | — | — | — | $6.65 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Q32 Bio Inc is a clinical-stage biotechnology company developing antibody-based therapeutics for autoimmune and inflammatory diseases. The company targets key pathways in both adaptive immunity (T and B cells) and innate immunity to restore immune balance. Q32's approach is designed to provide safe and effective treatment options for patients with pathological immune dysfunction.